# OAT Dispensing and Witnessed Doses in BC

CPBC rules for opioid agonist treatment: required training, the part-fill signing log, witnessed ingestion, take-home doses, and missed doses.

Last updated September 24, 2026.
Canonical HTML version: https://pharmflow.io/guides/oat-dispensing

Opioid agonist treatment (OAT) covers buprenorphine/naloxone (BMT), methadone (MMT), slow release oral morphine (SROM), and injectable opioid agonist treatment. Schedule E.12 of the College of Pharmacists of BC (CPBC) bylaws under the Health Professions Occupations Act sets the practice standards.

The CPBC OAT Practice Guides carry the detailed rules for releasing a dose, witnessing ingestion, handling take-home doses, and recording each part-fill.

- Source: [HPOA Bylaws, Schedule E.12 Opioid Agonist Treatment (CPBC)](https://library.bcpharmacists.org/6_Resources/6-1_Provincial_Legislation/5322-HPOA_Bylaws.pdf) (read 2026-09-24)
- Source: [OAT Practice Guides, Regulatory Statement RS26-008 (CPBC)](https://library.bcpharmacists.org/6_Resources/6-2_Regulatory_Statements/5330-RS26-008_OAT_Practice_Guides.pdf) (read 2026-09-24)

## Where the rules live

Schedule E.12 of the HPOA Bylaws took effect April 1, 2026 and replaced the former PPP-66. The College's Table of Concordance maps each retired Professional Practice Policy to the current instrument.

Schedule E.12 requires staff to apply the current OAT Practice Guides. The guides hold the mandatory practice requirements for each drug.

- Source: [HPOA Bylaws, Schedule E.12 Opioid Agonist Treatment (CPBC)](https://library.bcpharmacists.org/6_Resources/6-1_Provincial_Legislation/5322-HPOA_Bylaws.pdf) (read 2026-09-24)
- Source: [OAT Practice Guides, Regulatory Statement RS26-008 (CPBC)](https://library.bcpharmacists.org/6_Resources/6-2_Regulatory_Statements/5330-RS26-008_OAT_Practice_Guides.pdf) (read 2026-09-24)
- Source: [Table of Concordance, PPP to Bylaw (CPBC)](https://library.bcpharmacists.org/6_Resources/6-2_Regulatory_Statements/5336-Table_of_Concordance_PPP_to_Bylaw.pdf) (read 2026-09-24)

## Training before the first OAT service

- Every pharmacy manager, staff pharmacist, and relief pharmacist at an OAT pharmacy completes a board-approved OAT training program and records a self-declaration in eServices.
- Every pharmacy technician meets the same training and self-declaration requirement.
- The pharmacy manager educates all non-pharmacist staff about their OAT role and keeps a signed and dated record for each person.

- Source: [HPOA Bylaws, Schedule E.12 Opioid Agonist Treatment (CPBC)](https://library.bcpharmacists.org/6_Resources/6-1_Provincial_Legislation/5322-HPOA_Bylaws.pdf) (read 2026-09-24)

## Releasing a dose

- A pharmacist must be present to release the prescription.
- The client and the pharmacist sign a client and prescription-specific log for each release. Every part-fill is accounted for on one document.
- Neither the pharmacist nor the client may pre-sign for future doses or backdate a signing.
- Completed logs are filed in sequence by the first prescription or transaction number.

- Source: [OAT Practice Guides, Regulatory Statement RS26-008 (CPBC)](https://library.bcpharmacists.org/6_Resources/6-2_Regulatory_Statements/5330-RS26-008_OAT_Practice_Guides.pdf) (read 2026-09-24)

## Witnessed ingestion and take-home doses

- Methadone: the pharmacist directly observes the client ingest the dose and confirms the full dose was swallowed, followed by a short conversation.
- Buprenorphine/naloxone on a daily dispense order does not need observation. A Daily Witnessed Ingestion order means the pharmacist watches the client place the dose under the tongue.
- For methadone, the first take-home dose must be a witnessed ingestion. For buprenorphine/naloxone, the first carry needs no witnessing unless the prescriber orders it.
- Take-home doses go into child-resistant packaging with a warning label about the risk to others. Only the prescriber can authorize carries.

- Source: [OAT Practice Guides, Regulatory Statement RS26-008 (CPBC)](https://library.bcpharmacists.org/6_Resources/6-2_Regulatory_Statements/5330-RS26-008_OAT_Practice_Guides.pdf) (read 2026-09-24)

## Missed doses

- A dose prepared but not consumed or picked up on the prescribed day is missed. Reverse it in PharmaNet before the end of the business day.
- A missed dose cannot be given later. The pharmacist notifies the prescriber before the next scheduled release and keeps the notification on file.
- Methadone: 4 or more consecutive missed days cancels the prescription and the prescriber is notified.
- Buprenorphine/naloxone: the prescription is cancelled at 6 or more consecutive missed days without return to opioid use, or 4 or more consecutive days with return to opioid use.

- Source: [OAT Practice Guides, Regulatory Statement RS26-008 (CPBC)](https://library.bcpharmacists.org/6_Resources/6-2_Regulatory_Statements/5330-RS26-008_OAT_Practice_Guides.pdf) (read 2026-09-24)

## How PharmFlow tracks the signing queue

The OAT Signing page lists each dispensed dose with its dose type: witnessed, carry, or supervised. A pharmacist signs one entry or a selected batch. The server checks the pharmacist role, and a batch sign is all-or-nothing.

Each sign records the pharmacist name and time in the audit log. The client's signature on the part-fill log stays a counter step outside this page.

## Frequently asked questions

### Can a pharmacy technician sign for a released dose?

No. A pharmacist must be present to release the prescription, and the client and pharmacist sign the client and prescription-specific log for each release.

- Source: [OAT Practice Guides, Regulatory Statement RS26-008 (CPBC)](https://library.bcpharmacists.org/6_Resources/6-2_Regulatory_Statements/5330-RS26-008_OAT_Practice_Guides.pdf) (read 2026-09-24)
### Does every buprenorphine/naloxone dose need witnessing?

No. A daily dispense order does not require observation. Witnessing applies when the prescriber orders Daily Witnessed Ingestion.

- Source: [OAT Practice Guides, Regulatory Statement RS26-008 (CPBC)](https://library.bcpharmacists.org/6_Resources/6-2_Regulatory_Statements/5330-RS26-008_OAT_Practice_Guides.pdf) (read 2026-09-24)
### What happens when a client misses a dose?

Reverse the dose in PharmaNet the same business day and notify the prescriber before the next release. The missed dose cannot be given later.

- Source: [OAT Practice Guides, Regulatory Statement RS26-008 (CPBC)](https://library.bcpharmacists.org/6_Resources/6-2_Regulatory_Statements/5330-RS26-008_OAT_Practice_Guides.pdf) (read 2026-09-24)
### Who decides a client can take doses home?

Only the prescriber can authorize take-home doses. The pharmacist can raise concerns about carry readiness with the prescriber.

- Source: [OAT Practice Guides, Regulatory Statement RS26-008 (CPBC)](https://library.bcpharmacists.org/6_Resources/6-2_Regulatory_Statements/5330-RS26-008_OAT_Practice_Guides.pdf) (read 2026-09-24)
## Sources

- [HPOA Bylaws, Schedule E.12 Opioid Agonist Treatment (CPBC)](https://library.bcpharmacists.org/6_Resources/6-1_Provincial_Legislation/5322-HPOA_Bylaws.pdf) (read 2026-09-24)
- [OAT Practice Guides, Regulatory Statement RS26-008 (CPBC)](https://library.bcpharmacists.org/6_Resources/6-2_Regulatory_Statements/5330-RS26-008_OAT_Practice_Guides.pdf) (read 2026-09-24)
- [Table of Concordance, PPP to Bylaw (CPBC)](https://library.bcpharmacists.org/6_Resources/6-2_Regulatory_Statements/5336-Table_of_Concordance_PPP_to_Bylaw.pdf) (read 2026-09-24)
- [A Guideline for the Clinical Management of Opioid Use Disorder (BCCSU)](https://www.bccsu.ca/opioid-use-disorder/) (read 2026-09-24)